StreetInsider.com News Articles

Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report

Thu, 23 Jul 2026 15:30:00 -0400

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026.

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the

Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report

Thu, 23 Jul 2026 15:30:00 -0400

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the

Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report

Thu, 23 Jul 2026 15:30:00 -0400

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the

Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report

Thu, 23 Jul 2026 15:30:00 -0400

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the

Progyny (PGNY) PT Raised to $36 at Canaccord

Tue, 21 Jul 2026 06:43:05 -0400

Canaccord analyst Richard Close raised the price target on Progyny (NASDAQ: PGNY) to $36.00 (from $30.00) while maintaining a Buy rating.

Form 4 Progyny, Inc. For: Jul 14 Filed by: Cummings Melissa B

Thu, 16 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260716/26779891.html

Form 4 Progyny, Inc. For: Jul 14 Filed by: Cummings Melissa B

Thu, 16 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260716/26779891.html

Form 144 Progyny, Inc. Filed by: Cummings Melissa B

Tue, 14 Jul 2026 09:46:00 -0400

si-local-file:///var/storage/secattach/20260714/26766210.html

Form 144 Progyny, Inc. Filed by: Cummings Melissa B

Tue, 14 Jul 2026 09:46:00 -0400

si-local-file:///var/storage/secattach/20260714/26766210.html

'Progyny (PGNY) should have a nice beat and raise'; PT Raised to $35 at KeyBanc

Mon, 13 Jul 2026 07:22:57 -0400

(Updated - July 13, 2026 7:22 AM EDT)

KeyBanc analyst Scott Schoenhaus raised the price target on Progyny (NASDAQ: PGNY) to $35.00 (from $30.00) while maintaining an Overweight rating.

The analyst commented: "We believe PGNY should have a nice beat and raise supported by utilization topping consensus (we saw a nice acceleration in June in transactions & spend, see below). That said, we see the focus of the earnings call will be centered around the selling season, which we believe is continuing to see strength (particularly vs. last year). We believe PGNY is still targeting ~1 million added lives for next year

'Progyny (PGNY) should have a nice beat and raise'; PT Raised to $35 at KeyBanc

Mon, 13 Jul 2026 07:22:57 -0400

(Updated - July 13, 2026 7:22 AM EDT)

KeyBanc analyst Scott Schoenhaus raised the price target on Progyny (NASDAQ: PGNY) to $35.00 (from $30.00) while maintaining an Overweight rating.

Form 4 Progyny, Inc. For: Jun 17 Filed by: Clapp Geoffrey

Tue, 23 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260623/26679521.html

Form 4 Progyny, Inc. For: Jun 17 Filed by: Clapp Geoffrey

Tue, 23 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260623/26679521.html

Progyny (PGNY) PT Raised to $33 at Truist Securities

Mon, 22 Jun 2026 09:49:57 -0400

(Updated - June 22, 2026 9:49 AM EDT)

Truist Securities analyst Jailendra Singh raised the price target on Progyny (NASDAQ: PGNY) to $33.00 (from $30.00) while maintaining a Buy rating.

The analyst commented: "Fertile Ground for Sustained Growth and Share Gains; Detailed 2-Day NDR Takeaways: We hosted Progyny (PGNY) management - CEO Pete Anevski, CFO Mark Livingston, and VP of IR James Hart - for two days of Midwest investor meetings in Chicago and Minneapolis. The key message from these meetings was that the company remains a highly differentiated fertility benefits platform, built around superior clinical outcomes, comprehensive member support, and deep

Progyny (PGNY) PT Raised to $33 at Truist Securities

Mon, 22 Jun 2026 09:49:57 -0400

(Updated - June 22, 2026 9:49 AM EDT)

Truist Securities analyst Jailendra Singh raised the price target on Progyny (NASDAQ: PGNY) to $33.00 (from $30.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A Progyny, Inc. Filed by: KLEINER PERKINS CAUFIELD & BYERS XIII, LLC

Mon, 08 Jun 2026 12:26:00 -0400

si-local-file:///var/storage/secattach/20260608/26616201.html

Form SCHEDULE 13G/A Progyny, Inc. Filed by: KLEINER PERKINS CAUFIELD & BYERS XIII, LLC

Mon, 08 Jun 2026 12:26:00 -0400

si-local-file:///var/storage/secattach/20260608/26616201.html

Form 4 Progyny, Inc. For: Jun 03 Filed by: Anevski Peter